GlassScriptPhysician profile
Charlotte B High
NPI 1700206398
$1,375.78
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,242 · 2022: $28.58 · 2023: $53.39 · 2024: $51.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.20 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.08 | 2021 | |
| Novo Nordisk INC | $169.93 | 2021-2024 | |
| Lilly USA, LLC | $142.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $136.32 | 2021 | |
| Esperion Therapeutics, INC. | $111.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.25 | 2021 | |
| Vivus LLC | $45.18 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.43 | 2021 | |
| Sk Life Science, INC. | $36.75 | 2024 | |
| Antares Pharma, INC. | $29.71 | 2021 | |
| Merck Sharp & Dohme LLC | $29.16 | 2021 | |
| Dexcom, INC. | $22.85 | 2021 | |
| Clarus Therapeutics INC. | $21.66 | 2021 | |
| Insulet Corporation | $20.06 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.26 | 2021 | |
| Amgen INC. | $15.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.89 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.